Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Therapy of High Grade Glioma with Dendritic Cell Vaccination (Phase II)
2007-003513-14Phase 2Active
- Sponsor
- Karolinska University Hospital
- Start
- May 2008
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine in high-grade glioma (HGG), sponsored by Karolinska University Hospital. Primary endpoints: Overall survival, Progression-free survival and 3 more. Started May 2008; status: active.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on 2007-003513-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003513-14.